New in FY2027 GLP-1 Medication Coverage for the Treatment of Obesity Coverage for GLP-1 medications prescribed for the treatment of obesity only, under GIC health plans, will end at the end of Fiscal Year 2026 (FY3036), June 30, 2026 for non-Medicare plan members and on December 31, 2026 for Medicare plan members
SAM controls gene expression by binding to structural domains embedded within the non-coding region of certain mRNAs
Because their use extends beyond diabetes into obesity, MASLD, and potentially neurodegenerative disorders, characterizing both common and rare adverse effects across diverse populations and treatment durations is essential
Sourced from high-quality production, our high-purity Glutathione Powder is your key ingredient for formulating cutting-edge health and beauty products [1]
Retatrutide Dosage and Cardiometabolic Biomarker Effects Beyond body weight reduction, the Phase 2 clinical data provide insight into how retatrutide dosage affects a range of cardiometabolic biomarkers